Scientists have identified a protein that appears to put the brakes on chronic inflammation linked to aging, with older mice that received boosted levels becoming stronger, more energetic and developing healthier bones than untreated animals. The research, published in the journal Aging and Disease, points to a promising new target for therapies that could help people stay healthier and more independent later in life.
The protein at the center of the discovery is tristetraprolin, known as TTP, which binds to RNA and plays a critical role in regulating the body's inflammatory responses. In healthy individuals, TTP helps limit inflammatory signals that can damage tissues over time. However, levels of the protein tend to decline significantly with age, particularly in immune cells, leaving the body increasingly vulnerable to the chronic low-grade inflammation that drives many age-related diseases including arthritis, cardiovascular disease and neurodegeneration.
To test whether maintaining TTP levels could counteract these effects, researchers genetically modified a group of older mice so that the protein remained stable rather than declining as it normally does with age. The results showed that mice with stabilized TTP experienced markedly lower levels of physical frailty compared with untreated animals of the same age. The treated mice demonstrated greater muscle strength, higher activity levels and significantly improved bone density, suggesting that TTP plays a far more central role in the aging process than previously understood.
The findings build on earlier research at Imperial College London that found turning off a related inflammatory protein could extend healthy lifespan in mice. Together, these studies are constructing a clearer picture of how chronic inflammation accelerates aging at the cellular level and how targeted interventions might slow or partially reverse that process. Scientists emphasize that the approach differs from simply suppressing the immune system, which would leave individuals vulnerable to infections. Instead, stabilizing TTP appears to restore a more youthful balance to the inflammatory response without compromising immune function.
While human clinical applications remain years away, the research team said the results provide a strong foundation for developing drugs that could mimic the effect of boosted TTP levels in humans. Pharmaceutical companies have already expressed interest in the pathway, given the enormous potential market for treatments that address the root mechanisms of aging rather than individual age-related diseases. The researchers plan to begin preclinical trials of TTP-stabilizing compounds within the next two years, with the goal of eventually testing the approach in human patients suffering from age-related frailty and bone loss.
Comments